- Published at
- by manilatimes.net
neutral
neutral
News for ALK-Abelló A/S (AKBLF)
- Published at
- by seekingalpha.com
neutralneutralALK-Abelló A/S (AKBLF) Q4 2024 Earnings Call Transcript
ALK-Abelló A/S (OTCPK:AKBLF) Q4 2024 Results Conference Call February 19, 2025 7:30 AM ETCompany ParticipantsPer Plotnikof - Head of IRPeter Halling -...- Published at
- by seekingalpha.com
neutralneutralALK-Abelló A/S reports FY results (OTCMKTS:AKBLF)
ALK-Abelló A/S FY results: Revenue grew 15% to DKK 5.5B, driven by 24% tablet sales growth. European market momentum boosted performance.- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by investing.com
positivepositiveArs pharmaceuticals director Laura Shawver sells $555k in stock By Investing.com
Ars pharmaceuticals director Laura Shawver sells $555k in stock- Published at
- by gurufocus.com
positivepositiveARS Pharmaceuticals Expands Global Reach with Neffy Nasal Spray Approvals
ARS Pharmaceuticals Inc (SPRY), a biopharmaceutical company focused on empowering patients and caregivers against severe allergic reactions, announced on Januar- Published at
- by gurufocus.com
positivepositiveARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in- Published at
- by manilatimes.net
positivepositive- Published at
- by investing.com
positivepositiveArs Pharmaceuticals' chief business officer sells shares worth $657,625 By Investing.com
Ars Pharmaceuticals' chief business officer sells shares worth $657,625- Published at
- by investing.com
positivepositiveACARIZAX ® approved in Europe for treatment of young children By Investing.com
ACARIZAX ® approved in Europe for treatment of young children- Published at
- by investing.com
positivepositiveArs Pharmaceuticals' chief business officer sells $2.04 million in stock By Investing.com
Ars Pharmaceuticals' chief business officer sells $2.04 million in stock- Published at
- by investing.com
positivepositiveArs Pharmaceuticals' chief business officer sells $1.2 million in stock By Investing.com
Ars Pharmaceuticals' chief business officer sells $1.2 million in stock- Published at
- by globenewswire.com
positivepositiveFood Allergy Treatment Drug Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies - Vedanta Biosciences, Novartis, Alladapt Immunotherapeutics, Regeneron Pharmaceuticals, Ge
The overall dynamics of the food allergy market are anticipated to change in the coming years owing to the expected launch of emerging therapies like...- Published at
- by globenewswire.com
mixedmixedEpinephrine Market Size to Surpass USD 4.08 Billion by 2030, at a CAGR of 11.3%
As per the report by Fortune Business Insights, The Epinephrine Market size is projected to reach USD 4.08 Billion by 2030, at a CAGR of 11.3% during the...- Published at
- by globenewswire.com
mixedmixedPeanut Allergy Market to Accelerate Substantially by 2032, Examines DelveInsight | Leading Companies - Vedanta, Allergy, COUR Pharmaceutical, DBV, Aimmune, Novartis, NIAID, Alladapt Immunotherapeutics
The dynamics of the peanut allergy market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising...